Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response correctly states that CEQUA is indicated to increase tear production in keratoconjunctivitis sicca (dry eye) and appropriately cites label support. No contradictions were identified within the scope of the claims made.
Category Scores
Accurate Statements
CEQUA is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Section 1 INDICATIONS AND USAGE: 'indicated to increase tear production' in keratoconjunctivitis sicca (dry eye); Section 11 DESCRIPTION: calcineurin inhibitor immunosuppressant.
The claim is supported by labeling that reports statistically significant improvements vs vehicle in Schirmer wetting.
Section 14 CLINICAL STUDIES: statistically significant higher percentage of eyes with increases of ≥10 mm from baseline in Schirmer wetting vs vehicle.
There are no contraindications for CEQUA (label lists 'None.').
Section 4 CONTRAINDICATIONS: 'None.'
Unsupported Statements
Contradictions
Important Omissions
No dosing, administration, contact lens, warnings/precautions, adverse reactions, or population-specific safety statements were evaluated because the AI response did not make such claims.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims relate to the approved indication/efficacy framing and the absence of contraindications; no safety-impacting dosing or precautionary errors were asserted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement